Utama › Limfoma Sel Besar Anaplastik › North Carolina
Kajian klinikal Limfoma Sel Besar Anaplastik di North Carolina
5 kajian untuk Limfoma Sel Besar Anaplastik sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
Mengambil pesertaFasa 1/2
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04094610Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- North Carolina Cancer Hospital, Chapel Hill
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- dan 15 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06724237Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- dan 4 lagi
Mengambil pesertaKajian pemerhatian
Umur 65 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT01137825Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 120 · Semua jantina · Dikemas kini 27 Okt 2025 · NCT01137643Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.